Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2025, quý kết thúc ngày Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Adaptimmune Therapeutics's enterprise value was $55.27M on Oct 19, 2026, against $79.45M a year earlier. Over the last 5 years it ranged from $9.31M to $3.65B, with a median of $846.49M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Oct 19, 2026 | $55.27M | +34.9% |
| 2025 | Dec 31, 2025 | $40.96M | -94.1% |
| 2024 | Dec 31, 2024 | $690.72M | -24.5% |
| 2023 | Dec 29, 2023 | $915.00M | -25.8% |
| 2022 | Dec 30, 2022 | $1.23B | -62.3% |
| 2021 | Dec 31, 2021 | $3.27B | -28.9% |
| 2020 | Dec 31, 2020 | $4.60B | +607.8% |
| 2019 | Dec 31, 2019 | $649.97M | -80.7% |
| 2018 | Dec 31, 2018 | $3.36B | -4.4% |
| 2017 | Dec 29, 2017 | $3.52B | +136.0% |
| 2016 | Dec 30, 2016 | $1.49B | -69.5% |
| 2015 | Dec 31, 2015 | $4.89B | – |
See a number that looks wrong?